Skip to main content
← All Networks
ER

Epsilon Research

Expert Network · Founded 2017 · Boston, MA
Inference

Healthcare specialist expert network providing deep clinical and life sciences expertise to investors, pharmaceutical companies, and consultancies for due diligence and primary research.

Healthcare-only depth KOL identification Clinical due diligence Boston biotech hub
35K+
Experts
Positioning
80+
Employees
Inference
Per-call
Pricing
Verified

Services

Expert CallsHealthcare ResearchKOL IdentificationClinical Due Diligence

Best For

HealthcareLife SciencesPharma DD

When Not Ideal

Non-healthcare researchNeed sector diversityWant large generalist databaseNeed self-service platform

Key Strengths

  • ✓ Healthcare-only focus enables deeper therapeutic area expertise than generalist networks
  • ✓ KOL identification capabilities for pharma and biotech
  • ✓ Boston location provides access to world-class healthcare/biotech ecosystem
  • ✓ Clinical and regulatory expertise for investment due diligence

Watch-outs

  • ⚠ No coverage outside healthcare and life sciences
  • ⚠ Smaller expert database than generalist networks
  • ⚠ Limited public information about funding and scale
  • ⚠ Less suitable for broad market research spanning multiple sectors

Deep Dive

1 Overview
Epsilon Research is a Boston-based expert network that specializes exclusively in healthcare and life sciences. Founded in 2017, the company connects investors, pharmaceutical companies, and consulting firms with clinical experts, Key Opinion Leaders (KOLs), and scientific specialists for due diligence, primary research, and strategic advisory. The company's healthcare-only focus enables deeper expertise in therapeutic areas, clinical trial dynamics, regulatory pathways, and market access — areas where generalist expert networks often lack depth. Epsilon's KOL identification and mapping capabilities help pharmaceutical companies identify influential physicians and researchers in specific disease areas.
2 History

Epsilon Research was founded in 2017 in Boston, choosing to specialize exclusively in healthcare and life sciences rather than competing as a generalist. The company built its expert network through relationships with clinical researchers, physicians, regulatory specialists, and healthcare executives.

2017
Founded in Boston with exclusive healthcare and life sciences focus
2018-2022
Built healthcare expert network to 35K+; developed KOL mapping capabilities
2023-2025
Expanded clinical due diligence and therapeutic area coverage
3 Services in Detail

Healthcare Expert Consultations

One-on-one consultations with physicians, clinical researchers, regulatory specialists, and healthcare executives across therapeutic areas.

KOL Identification & Mapping

AI-powered identification and mapping of Key Opinion Leaders across therapeutic areas, analyzing publication records, clinical trial involvement, and conference activity.

Clinical Due Diligence

Expert-supported due diligence for healthcare investments, evaluating drug pipelines, clinical trial designs, regulatory risks, and market access strategies.

4 AI & Platform

Epsilon uses AI for KOL mapping and therapeutic area matching, analyzing clinical trial databases, publication records, and conference participation to identify healthcare experts.

  • ◆ AI-powered KOL mapping and identification
  • ◆ Clinical trial database analysis
  • ◆ Therapeutic area matching algorithms
  • ◆ Publication and citation analysis for expert credentialing
5 Compliance

Epsilon maintains healthcare-specific compliance protocols with strict safeguards for clinical trial information and pharma consulting conflicts.

  • ● Healthcare-specific MNPI policies
  • ● Clinical trial information safeguards
  • ● Rigorous credential verification for medical professionals
  • ● Pharma consulting conflict screening
  • ● Audit trail for all expert interactions
Regulatory Context

Healthcare expert consultations require careful handling of clinical trial data, FDA regulatory information, and pharma-specific conflicts. Clean regulatory record.

6 Client Fit

Ideal for organizations that need deep healthcare expertise. Not suitable for non-healthcare research.

  • → Life sciences investors evaluating drug pipelines and biotech targets
  • → Pharmaceutical companies seeking KOL identification and advisory
  • → Healthcare-focused PE/VC firms conducting clinical due diligence
  • → Medical device companies seeking regulatory and clinical expertise
7 Notable Facts
  • • Healthcare-only expert network — rare pure specialization in the industry
  • • KOL mapping combines publication analysis, clinical trial data, and conference activity
  • • Boston headquarters in the heart of the US biotech/pharma corridor
8 Source Notes & Methodology
  • ℹ Epsilon Research website — company overview and services
  • ℹ Expert network industry directories
  • ℹ INEX ONE Expert Network Directory
9 Data Confidence Ratings

Each data point in this profile is graded for source confidence. Here's what each badge means:

Verified Confirmed by official company disclosures, regulatory filings, or multiple independent sources.
Positioning Based on company marketing claims or self-reported data that could not be independently verified.
Inference Estimated or inferred from indirect evidence, third-party aggregators, or industry context.
Partially Unverifiable Some aspects verified but full claim cannot be independently confirmed (e.g., private company financials from third-party estimates).

This profile's ratings

founded: partially-unverifiable headquarters: verified expertCount: positioning employeeCount: partially-unverifiable pricingModel: verified services: positioning compliance: positioning overview: positioning history: inference servicesDetailed: positioning aiPlatform: positioning complianceExtended: positioning clientFit: inference strengths: positioning caveats: inference notableFacts: positioning
10 How We Researched This

This profile was researched and written by the ExpertNetworks.net editorial team using a multi-source methodology:

  1. Primary sources: Company website, press releases, SEC/regulatory filings, and official announcements
  2. Third-party verification: Industry reports (Integrity Research, Inex One), news coverage (TechCrunch, Bloomberg, FT), and data aggregators (PitchBook, Tracxn, Crunchbase)
  3. Cross-referencing: Claims were checked against multiple independent sources where possible; single-source claims are flagged
  4. Confidence grading: Each data point is rated as Verified, Positioning (company-claimed), or Inference (estimated from indirect evidence)

We do not accept payment from any expert network for inclusion or favorable coverage. If you spot an error, contact us with the correction and source.

Last fact-checked: 2026-03-07

Industries Served

HealthcareLife SciencesPharmaceuticalsMedical DevicesBiotechnology

Compare Epsilon Research

vs G vs A vs D vs TB vs GP
Full comparison with all providers →
Visit Epsilon Research →
Last updated: 2026-03-07